

Plasma Transcortin Influences Endocrine and Behavioral Stress Responses in Mice

Elodie M. Richard, Jean-Christophe Helbling, Claudine Tridon, Aline Desmedt, Amandine M. Minni, Martine Cador, Line Pourtau, Jan-Pieter Kongsman, Pierre Mormède, and Marie-Pierre Moisan

Institut National de la Recherche Agronomique (INRA) (E.M.R., J.-C.H., C.T., A.M.M., L.P., P.M., M.-P.M.), Unité Mixte de Recherche (UMR) 1286 PsyNuGen, and Centre National de la Recherche Scientifique (CNRS) (J.-P.K.), UMR 5226, Université de Bordeaux 2, F-33076 Bordeaux, France; CNRS (A.D.), UMR 5228, Centre de Neurosciences Intégratives et Cognitives, Université Bordeaux I, F-33405 Talence, France; and CNRS (M.C.), UMR 5227 Psychobiologie des Desadaptations, Université de Bordeaux 2, F-33076 Bordeaux, France

Glucocorticoids are released after hypothalamus-pituitary-adrenal axis stimulation by stress and act both in the periphery and in the brain to bring about adaptive responses that are essential for life. Dysregulation of the stress response can precipitate psychiatric diseases, in particular depression. Recent genetic studies have suggested that the glucocorticoid carrier transcortin, also called corticosteroid-binding globulin (CBG), may have an important role in stress response. We have investigated the effect of partial or total transcortin deficiency using transcortin knockout mice on hypothalamus-pituitary-adrenal axis functioning and regulation as well as on behaviors linked to anxiety and depression traits in animals. We show that CBG deficiency in mice results in markedly reduced total circulating corticosterone at rest and in response to stress. Interestingly, free corticosterone concentrations are normal at rest but present a reduced surge after stress in transcortin-deficient mice. No differences were detected between transcortin-deficient mice for anxiety-related traits. However, transcortin-deficient mice display increased immobility in the forced-swimming test and markedly enhanced learned helplessness after prolonged uncontrollable stress. The latter is associated with an approximately 30% decrease in circulating levels of free corticosterone as well as reduced *Egr-1* mRNA expression in hippocampus in CBG-deficient mice. Additionally, transcortin-deficient mice show no sensitization to cocaine-induced locomotor responses, a well described corticosterone-dependent test. Thus, transcortin deficiency leads to insufficient glucocorticoid signaling and altered behavioral responses after stress. These findings uncover the critical role of plasma transcortin in providing an adequate endocrine and behavioral response to stress. (*Endocrinology* 151: 649–659, 2010)

Adaptive responses to stress are essential for life and involve activation of a complex repertoire of autonomic, neuroendocrine, and behavioral responses, originating both from the brain and the periphery, that work in concert to reinstate homeostasis. If these adaptive systems are overactive or fail to respond appropriately, psychiatric diseases, such as affective disorders, cognitive impairment, or vulnerability to drug addiction, may develop in vulnerable individuals (1–4). Important individual differences are observed in the ability of an individual to cope

with stressful events. This variability depends on genetic, environmental (in particular during the perinatal period), and epigenetic factors (5, 6).

A major system involved in adaptive stress responses is the hypothalamus-pituitary-adrenal (HPA) axis (3, 7). Under normal physiological conditions, glucocorticoid (cortisol in humans, corticosterone in laboratory rodents) secretion follows a circadian rhythm entrained by light and food intake that stimulate the secretion of the hypothalamic peptide corticotrophin-releasing hormone

ISSN Print 0013-7227 ISSN Online 1945-7170
Printed in U.S.A.

Copyright © 2010 by The Endocrine Society
doi: 10.1210/en.2009-0862 Received July 22, 2009. Accepted November 11, 2009.
First Published Online December 18, 2009

Abbreviations: Bmax, CBG maximal binding capacity; CBG, corticosteroid-binding globulin; CRH, corticotrophin-releasing hormone; GR, glucocorticoid receptor; HPA, hypothalamus-pituitary-adrenal; MR, mineralocorticoid receptor.

(CRH), which, in turn, triggers pituitary secretion of ACTH that acts on adrenal glands to stimulate glucocorticoid release in the blood. In plasma, glucocorticoids bind with a high affinity but low capacity to transcortin, also called corticosteroid-binding globulin (CBG), and to albumin with a high capacity but low affinity. The free fraction of circulating glucocorticoids thus constitutes around 5% of the total glucocorticoid pool. Free glucocorticoids regulate negatively their own secretion by inhibiting CRH and ACTH release, and act on target tissues by binding to two nuclear receptors, the mineralocorticoid (MR) and the glucocorticoid receptors (GRs). Under stressful conditions, the rise in CRH levels results in transiently increased glucocorticoid secretion. The free fraction of circulating glucocorticoids is then more than proportionally increased because stress-induced glucocorticoid secretion overshoots transcortin binding capacity (8).

We have shown by genetic linkage analysis in pig models that the variability in stress-induced glucocorticoid levels depends strongly on a genomic locus containing the *Cbg* gene encoding transcortin (9). On further investigations, we have accumulated data favoring the hypothesis that *Cbg* gene polymorphism is indeed responsible for variability in stress-induced glucocorticoid levels in our pig models (10, 11). This genetic association between glucocorticoid stress levels and the genomic locus of *Cbg* gene has been replicated by an independent group in rat models (12). Thus, this set of data prompted us to create a rodent model of *Cbg* gene deficiency, in which *Cbg* gene expression is specifically modified, and to study, in more details than could be done in humans, its influence on HPA axis regulation and stress-induced behavioral responses. In this report, we present data showing the importance of CBG in defining glucocorticoid pool size as well as free glucocorticoid concentrations. Additionally, we show that these endocrinological alterations are associated with behavioral deficits.

Materials and Methods

Generation of *Cbg*-deficient mice

Cbg floxed mice were constructed at the Mouse Clinical Institute (Illkirch, France). Exon 2 of the mouse *Serpina6* gene encoding CBG was flanked by loxP sites using homologous recombination in embryonic stem cells to obtain *Cbg* floxed mice. The *Cbg* floxed mice were then sent to our laboratory in Bordeaux and backcrossed with C57BL/6J mice from Charles River (L'Arbresle, France). For the inactivation of CBG in all cells, we crossed CMV-Cre transgenic mice (13) with *Cbg* floxed mice. *Cbg*^{+/+}, *Cbg*^{+/-}, and *Cbg*^{-/-} mice were obtained by breeding *Cbg*^{+/-} males and females. All mice used in the present work are males and have a C57BL/6J genetic background above 90%. Animals were maintained in an animal room (23 C) with a 12-h light-dark cycle (lights on at 0700 h) and with *ad libitum* access

to food and water. All the experiments were conducted in strict compliance with current European Conventions and approved by Institutional Committee. The numbers of animals tested in each experiment were dependent on the availability of male mice of approximately the same age for each genotype.

Neuroendocrinological experiments

Mice were housed individually for a week before the experiments.

Circadian experiments

Blood samples were collected by tail nick every 4 h. Time from first handling to completion of this procedure did not exceed 2 min to obtain basal levels of corticosterone and CBG. A preliminary experiment done on eight C57BL/6J male mice confirmed that this procedure allowed us to obtain basal levels because we got the same values as others who used different groups of animals at each time point. Blood was collected in EDTA solution (0.1% final concentration), and plasma, recovered after 10 min centrifugation of blood samples, was kept at -80 C. To measure free corticosterone, mice were anesthetized with a rapid isoflurane exposure (Aerrane, Baxter SA, Maurepas, France) and blood collected by cardiac puncture in less than 20 sec either between 0900 h and 1000 h for morning concentrations or between 1900 h and 2000 h for evening concentrations.

Restraint stress

The animals were placed in a 50-ml conical tube (with holes allowing breathing) for 20 min, blood was collected by tail nick, and then the animals were returned to their home cage.

Behavioral experiments

All the tests were conducted between 0900 h and 1300 h. The same groups of mice, 3–5 months of age, were used successively for activity cages, elevated-plus-maze, and open field with at least 1-wk interval between tests. Naive 4-month-old male mice were used for learned helplessness and locomotor response to cocaine experiments. The learned helplessness test was replicated on a second independent group of 3–3.5 months of age with blood samples collected before, during (just before putting the animal in the shuttle box), and right after the test for corticosterone measurements. An independent group of naive 3-month-old mice was used for the forced-swimming tests.

Details of the tests procedures and materials are provided in the supplemental data published on The Endocrine Society's Journals Online web site at <http://endo.endojournals.org>.

Corticosterone and ACTH measurements

Total corticosterone in plasma was measured with an in-house RIA using a highly specific antibody provided by H. Vaudry (University of Rouen, France). Cross reactivity with related compound such as cortisol was less than 3%. Intraassay and interassay variations were less than 10% and less than 15%, respectively. Plasma free corticosterone was estimated by isotopic dilution and plasma ultrafiltration as described (14) with some modifications detailed in supplemental data. The distribution of ³H corticosterone between the different serum components (CBG and albumin) was calculated from measurements of the percentage of nonprotein bound corticosterone in treated and heat-treated serum (60 C for 1 h to eliminate CBG binding

activity) as described previously (15). Variations for the entire assay was of 13% intraassays and less than 15% interassays. All animals from an experiment were measured in the same assay to avoid interassay variation. ACTH levels were measured using a commercial kit (ACTH ¹²⁵I RIA Kit, ref 24130; Diasorin, Antony, France).

CBG binding capacity assay

CBG maximal binding capacity (B_{max}) was obtained by a saturation binding experiment as described (16) with some modifications detailed in supplemental data. Intraassay and interassay variations were less than 10% and less than 20%, respectively. All animals from an experiment were measured in the same assay to avoid interassay variation.

Western blot analysis of serum CBG and albumin

A total of 5 μg of protein from mice plasma was subjected to 10% SDS-PAGE (Ready gel; Bio-Rad, Marnes-la-Coquette, France) and electroblotted on a nitrocellulose membrane (Millipore, Molsheim, France). After 24 h of saturation at 4 C, membranes were incubated 1 h at room temperature with rabbit antimouse CBG antiserum diluted 1:1000 (gift from G. L. Hammond, University of British Columbia, Vancouver, Canada). After stripping of the bound CBG antiserum, the same membrane was incubated with rabbit antimouse albumin CLA3140 antiserum diluted 1:10000 (Cedarlane, Ontario, Canada). Specific antibody-antigen complexes were identified using a horseradish peroxidase-labeled antirabbit antibody (Santa Cruz Biotechnology, CA) and ECL+ detection reagents (PerkinElmer, Courtaboeuf, France). Chemiluminescence was captured by a Syngene detection system and quantified by Gene Tools software (Syngene, Cambridge, UK).

Gene expression by real-time PCR

Gene expression was evaluated by real-time PCR from reverse-transcribed total RNA. Detailed procedure and sequence of primers used are provided in supplemental Materials and Methods (see also supplemental Table S1). Total RNA was extracted from mice killed at 1900 h at the beginning of the dark phase for basal levels and from mice killed at the end of the learned helplessness test for stress levels. Relative quantification of target mRNA levels, normalized with 18S, was calculated with the SDS2.1 software (PerkinElmer, Courtaboeuf, France).

Statistics

Statistics were calculated with the software GraphPad Prism 5.0 (San Diego, CA). Data are presented as mean ± SEM. One-way ANOVA with Tukey post-hoc test was used for gene expression, CBG binding capacity, total and free corticosterone. Two-way ANOVA followed by Bonferroni post-hoc test was used for circadian variation of corticosterone in plasma and for kinetics of stress reactivity. Corticosterone data were log-transformed before analysis, and repeated measures parameter was used when appropriate. Nonparametric Kruskal-Wallis test was used for behavioral tests except for cocaine sensitization analyzed by two-way genotype × day ANOVA of repeated measures followed by paired *t* test within genotype. On graphs, *one symbol* (* or #) indicates a *P* < 0.05, *two symbols* *P* < 0.01, and *three symbols* *P* < 0.001.

Results

Generation of transcortin-deficient mice

Cre/loxP system was used to obtain Cbg floxed mice that were bred with the previously described CMV-Cre transgenic mice (13) to obtain Cbg knockout animals. Cbg^{+/+}, Cbg^{+/-}, and Cbg^{-/-} mice were littermates obtained by breeding Cbg^{+/-} males and females. Successful knockout of CBG gene was confirmed by several experiments (Fig. 1). Quantitative real-time PCR showed no expression of Cbg gene in liver of Cbg^{-/-} mice and 50% of mRNA levels in Cbg^{+/-} compared with wild type (ANOVA *F* = 21.5, *P* < 0.0001) (Fig. 1A). This was confirmed by Western blot analysis on plasma of three animals of each genotype using a specific mouse CBG antiserum (Fig. 1B). Albumin was revealed on the same membrane using a specific mouse albumin antiserum. No quantitative differences were found between genotype for albumin levels. Finally, CBG maximal binding capacity was assessed in each genotype. In wild-type males, values were found close to those previously reported: 136 ± 49 vs. 144 ± 21 (nM) in Cole *et al.* (17) for example. As expected, maximal binding capacity was found to be markedly decreased in Cbg^{-/-} mice, and Cbg^{+/-} animals show intermediate levels between wild type and Cbg^{-/-} (ANOVA *F* = 33.6, *P* < 0.0001) (Fig. 1C). The distribution of corticosterone bound to either CBG or albumin was estimated as described (15), considering that albumin binding is resistant to a 60 C heating treatment of plasma, whereas CBG binding is inactivated at this temperature (Fig. 1D). The percentage of corticosterone bound to albumin as well as the free fraction rose dramatically in Cbg^{-/-} and very moderately in Cbg^{+/-} compared with Cbg^{+/+}. In Cbg^{-/-} mice, we found residual “CBG” binding (Fig. 1, C and D) that probably relates to unspecific binding to heat labile proteins in plasma.

HPA axis basal activity

The consequences of CBG deficiency on basal HPA activity were addressed by measuring total corticosterone during the diurnal cycle in animals fed *ad libitum* (Fig. 2A). By two-way analysis on log-transformed total corticosterone data, we found a genotype × time interaction not quite significant (*F*_{8,71} = 2.0, *P* = 0.06), a very significant genotype effect (*F*_{2,71} = 18.4, *P* < 0.0001) and time effect (*F*_{4,71} = 26.8, *P* = 0.0001). By using Bonferroni post-tests, no difference in total plasma corticosterone was detected between wild-type and heterozygous Cbg^{+/-} mice at any time. However, Cbg^{-/-} animals showed markedly reduced levels of plasma corticosterone at the end of the light and beginning of the dark phase compared with Cbg^{+/+} and Cbg^{+/-} (*P* < 0.01). Total and free corticosterone levels were estimated in the plasma of new groups of mice




FIG. 1. Generation of mice deficient in transcortin. A, Cbg mRNA expression in liver of Cbg+/+, Cbg+/-, and Cbg-/- mice measured by real-time PCR (n = 6 per group). B, Western blots on plasma from each genotype using mouse albumin and Cbg antisera. C, Bmax to corticosterone estimated by saturation curve in plasma (n = 6 per genotype). D, Distribution of corticosterone binding in plasma estimated by isotopic dilution and ultrafiltration (n = 6 per genotype). Tukey post-hoc tests: *, P values of Cbg-/- or Cbg+/- vs. Cbg+/+; #, P values of Cbg-/- vs. Cbg+/- . One symbol indicates a P < 0.05, two symbols P < 0.01, and three symbols P < 0.001.

killed either in the morning (0900 h) or in the evening at the beginning of the dark phase (1900 h). Total corticosterone levels were similar to those reported in Fig. 2A. The free fraction of corticosterone, measured by isotopic dilution and plasma ultrafiltration, was $7.1 \pm 0.4\%$ in Cbg+/+, $8.7 \pm 0.8\%$ in Cbg+/-, and $20.5 \pm 0.3\%$ in Cbg-/- mice in the morning and $9.4 \pm 0.6\%$ in Cbg+/+, $12.3 \pm 0.9\%$ in Cbg+/-, and $26.0 \pm 1.3\%$ in Cbg-/- in the evening. Morning concentrations of free corticosterone, derived from the free fraction and the total corticosterone concentrations, were significantly higher in Cbg-/- compared with wild type and Cbg+/- (2.7 ± 0.1

nm vs. 1.1 ± 0.1 nm and 0.8 ± 0.1 nm, respectively, $F = 108.0$; $P < 0.0001$) as expected because there were no differences in total corticosterone levels. Conversely, in the evening, corresponding to the active phase of nocturnal animals such as mice, no variation in free corticosterone concentrations was detected between groups ($F = 0.15$, $P = 0.85$) (Fig. 2B). No significant differences were detected between groups for ACTH levels neither in the morning ($P = 0.09$) nor in the evening ($P = 0.70$) (Fig. 2C). The mRNA expression of some corticosteroid target genes [phosphoenolpyruvate carboxykinase (PEPCK), tyrosine aminotransferase (TAT), angiotensinogen, GR in liver]




FIG. 2. Plasma corticosterone and ACTH levels at rest in transcortin-deficient mice. A, Total plasma corticosterone levels across the circadian cycle (n = 5–7 per group). Thicker line on x-axis indicates time when lights were off. B, Free plasma corticosterone levels in the morning (n = 5–6 per group) and in the evening (n = 7–8 per group) from mice of each genotype. C, Plasma ACTH levels (n = 8–10 per group). *, Post hoc P values of Cbg-/- or Cbg+/- vs. Cbg+/+; #, P values of Cbg-/- vs. Cbg+/- only. One symbol indicates a P < 0.05, two symbols P < 0.01. ns, Not significant.




FIG. 3. Plasma corticosterone and ACTH levels after stress in transcortin-deficient mice. A, Total corticosterone levels at different time points (n = 5 per genotype and time point) after 20-min restraint stress. B, Free corticosterone levels after 20-min restraint stress (n = 7–8 per genotype). C, ACTH levels after stress (n = 5–6 per group). *, *Post hoc* P values of Cbg^{-/-} or Cbg^{+/-} vs. Cbg^{+/+}; #, P values of Cbg^{-/-} vs. Cbg^{+/-} only. One symbol indicates a P < 0.05, two symbols P < 0.01, and three symbols P < 0.001. ns, Not significant.

and/or genes involved in the HPA axis regulation [CRH receptor 1 (CRHR1), proopiomelanocortin (POMC), GR in pituitary; CRH, GR in hypothalamus, CRHR1, GR, MR in hippocampus] was estimated by real-time PCR in tissues dissected from animals killed in the evening (supplemental Table S2). No significant difference was found between genotypes for any genes in any tissues tested.

HPA axis reactivity to stress

After a 20-min restraint stress, there was no significant genotype x time interaction by two-way ANOVA analysis on log-transformed data of total corticosterone values ($F_{8,55} = 1.6$; $P = 0.14$) (Fig. 3A). However, there were significant genotype ($F_{2,55} = 27.5$; $P < 0.0001$) and time ($F_{4,55} = 40.4$; $P < 0.0001$) effects. Cbg^{-/-} and Cbg^{+/-} mice showed altered levels of corticosterone response after stress with reduced peak levels compared with Cbg^{+/+} (115.9 ± 15.6 nM in Cbg^{-/-}, 229.6 ± 54.6 nM in Cbg^{+/-}, and 508.7 ± 67.4 nM in Cbg^{+/+} at $t = 20$ min). After 20-min stress, significant differences in free corticosterone levels were detected between genotypes: Cbg^{+/+} = 78.4 ± 5.5 nM, Cbg^{+/-} = 57.5 ± 6.0 nM, and Cbg^{-/-} = 50.9 ± 5.4 nM (ANOVA, $F = 6.75$, $P = 0.006$, Fig. 3B).

Thus, free corticosterone levels increase after stress in all groups compared with basal levels (~15–18 nM for each group at rest; Fig. 2) but to a lesser extent in transcortin-deficient mice. ACTH levels showed a tendency for higher levels in CBG-deficient mice as expected although the difference was not significant ($P = 0.07$) between groups (Fig. 3C).

Behavioral reactivity to mild stress

To evaluate the impact of CBG deficiency on behavioral reactivity, groups of mice from each genotype were submitted to a battery of moderately stressful behavioral tests. Cbg^{+/-} and Cbg^{-/-} mice exhibited behaviors indistinguishable from their wild-type littermates in the activity cage and open field tests that provide measures of locomotion and exploration under moderate stress (Fig. 4 and supplemental Fig. S1). In addition, mice from all genotypes showed similar anxiety-related behavior as measured in the time spent in the center of the open-field (supplemental Fig. S1) and the time or frequency of entries in the open arms of the elevated-plus-maze test (supplemental Fig. S2).




FIG. 4. Locomotor activity of transcortin-deficient mice. A, Locomotor activity in a novel environment was evaluated after the first exposure to activity cages during 3 h. B, Basal locomotor activity was measured during 3 d in activity cages after 3 h of habituation to the cages. n = 10–12 per group.




FIG. 5. Learned helplessness behavior in transcortin-deficient mice. Learned helplessness was evaluated in a shuttle box after exposure to two sessions of inescapable footshocks. The combined results of two independent groups are presented ($n = 15\text{--}18$ per genotype). *, *Post hoc* P values of Cbg+/- or Cbg-/- vs. Cbg+/+. One symbol indicates a $P < 0.05$, two symbols $P < 0.01$. nb, Number.

Depression-like behavior after intense and uncontrollable stress

We used the learned helplessness paradigm to evaluate despair-like behavior after an intense and uncontrollable stress. This paradigm is reported to show very good face validity and to have a good predictive validity for depressive states with both benzodiazepines and lithium being effective in reversing helplessness (18). After two sessions of unpredictable and uncontrollable footshocks performed on 2 consecutive days, learned helplessness behavior was assessed by the number of escape failures, escapes in reaction to the footshock, and avoidances in a shuttle box. The test was duplicated in two independent groups of mice and showed a similar pattern of responses. Thus, the data were combined for final analysis (Fig. 5). Compared with wild-type mice, Cbg mutant mice displayed a significantly increased number of escape failures (Kruskal-Wallis test, $P = 0.002$). In addition, there was a tendency for a lower number of escapes in reaction to the footshocks in both Cbg mutant mice ($P = 0.07$). Finally, the number of avoidances was significantly decreased in both Cbg+/- and Cbg-/- compared with wild types ($P = 0.0015$). On the second group of mice tested for learned helplessness, we have collected blood samples to evaluate corticosterone levels in the mice. Blood samples were collected by tail nick first just before the test for basal values, then the morning after the footshock sessions, *i.e.* just before the mice were submitted to the shuttle box, and finally by cardiac puncture at the end of the experiment when ani-

mals were killed. Free corticosterone and CBG were evaluated only at killing time because high plasma volume is required for the assays, and tissues were collected for gene expression analysis. The results are summarized in Table 1. Total corticosterone values before the test are in accordance with expected basal corticosterone morning levels. In the morning after the 2 d of footshocks, total corticosterone values were elevated in all groups. Just after the shuttle box test at the end of the whole experiment, total corticosterone levels were greatly elevated for all groups with lower levels for CBG-deficient mice ($F = 31.3$, $P < 0.0001$) as expected from Fig. 3. The free fraction of corticosterone was greatly increased in Cbg+/+ and Cbg+/- but moderately in Cbg-/- animals compared with the values observed in unstressed animals. In terms of concentrations, free corticosterone was found significantly reduced in Cbg-deficient mice compared with wild type ($F = 3.5$, $P < 0.05$), 22% decrease for Cbg+/-, and 31% for Cbg-/. Additionally, we found a positive correlation between the number of avoidances observed in the learned helplessness test and the free corticosterone concentration ($r = 0.43$, $P < 0.05$; see supplemental Fig. S3). To evaluate whether this reduced free corticosterone in plasma translates into reduced glucocorticoid gene activation in the brain, we evaluated the expression of various genes in brain tissues of the mice dissected after the learned helplessness test (Table 1 and supplemental Fig. S3). Significant differences between genotypes were detected for Egr-1 mRNA in hippocampus with an approximately 40% decrease in transcortin-deficient mice compared with controls.

TABLE 1. Corticosterone, CBG during the learned helplessness test

	CBG+/+ $n = 7$	CBG+/- $n = 8$	CBG-/- $n = 9$	P (ANOVA)
Total [B] before LH test (d 1) (nM)	12.0 \pm 2.3	9.2 \pm 1.4	13.6 \pm 1.1	NS
Total [B] before LH shuttle test (d 2) (nM)	25.2 \pm 4.9	31.2 \pm 7.9	19.6 \pm 3.0	NS
Total [B] after LH test (d 3) (nM)	363.5 \pm 20.2	253 \pm 19.7	179.5 \pm 9.1	$P = 0.0001$
% free B after LH test (d 3)	19.9 \pm 0.7	22.2 \pm 3.3	27.5 \pm 2.0	$P = 0.09$
Free [B] after LH test (d 3) (nM)	72.0 \pm 3.6	55.6 \pm 8.5	49.7 \pm 4.6	$P = 0.03$
CBG Bmax after LH test (d 3) (nM)	133.8 \pm 9.1	91.5 \pm 15.4	36.7 \pm 2.3	$P = 0.004$
Egr-1 mRNA expression in hippocampus (relative mRNA abundance)	1.21 \pm 0.16	1.06 \pm 0.13	0.73 \pm 0.11	$P = 0.04$

LH, Learned helplessness; NS, not significant.




FIG. 6. Passive coping behavior of transcortin-deficient mice in the Porsolt forced-swimming test. Floating behavior was evaluated for 6 min in 25°C water ($n = 7$ – 10 per genotype) on two consecutive days and on d 4 after exposure to restraint stress. *, *Post hoc* P values of Cbg^{-/-} vs. Cbg^{+/-}. One symbol indicates a $P < 0.05$. FST, Forced swimming test.

To evaluate the helplessness behavior in a different paradigm, we have submitted new groups of mice to the forced-swimming test (Fig. 6). On the first day of test, there was no significant difference between groups by Kruskal-Wallis test, although a clear tendency for increased immobility of the Cbg^{-/-} mice is observed. This nonsignificant result can be explained by a great dispersion of Cbg^{+/-} mice scores as Cbg^{-/-} immobility time is significantly different from Cbg^{+/+} by t test ($P < 0.05$). The second day of test, Cbg^{+/+} and Cbg^{+/-} mice increased their levels of immobility to reach those of the Cbg^{-/-} mice. Forty-eight hours later, all mice were submitted to a 1-h restraint stress, then left undisturbed for 3 h before submitting them to the forced-swimming test. This procedure had been used by others (19) to stimulate the CRF system before the behavioral test. In these conditions, a significant effect of genotype was found by Kruskal-Wallis test ($P = 0.02$), both the Cbg^{+/+} and Cbg^{+/-} showed an active behavior with decreased immobility time, whereas the Cbg^{-/-} remained with high levels of immobility time.

Cocaine-induced sensitization

Locomotor response to cocaine-induced sensitization is a phenomenon known to be corticosterone-dependent in

rodents (4). Because our previous results suggested that CBG deficiency induces a glucocorticoid hyposignaling after stimulation of the HPA axis, we thought that cocaine-induced sensitization would be a good functional test of glucocorticoid signaling efficiency in the transcortin-deficient mice. To evaluate the role of CBG levels on cocaine sensitization, the locomotor response of mice after administration of saline or cocaine ip was measured in activity cages. Acute 20 mg/kg of cocaine administration produced a significant increase in locomotion in all groups with no difference between genotypes (Fig. 7A). However, sensitization to cocaine revealed differences between groups (two-way ANOVA, genotype \times day interaction: $F_{1,12} = 7.7$, $P = 0.017$). After repeated administration of 20 mg/kg of cocaine over 5 d, locomotion increased progressively in wild-type and Cbg^{+/-} mice, and a challenge given on d 14 produced a significant increase in locomotor activity in wild-type and a moderate rise in Cbg^{+/-} animals (paired t test d 14 vs. d 1 within a genotype, $P = 0.005$ and $P = 0.038$, respectively). However, this sensitization to cocaine in terms of locomotor response was found totally suppressed in Cbg^{-/-} mice ($P = 0.51$) (Fig. 7B).




FIG. 7. Locomotor response to cocaine administration in transcortin-deficient mice. A, Locomotor response to a single 20 mg/kg injection of cocaine was evaluated in activity cages for 2 h in mice of each genotype ($n = 6$ – 7 per group). B, Sensitization of locomotor response to cocaine was evaluated in mice of each genotype after repeated injections for 5 d of 20 mg/kg of cocaine and a challenge with the same dose at d 14 ($n = 6$ – 9 per group). *, t test P values comparing d 14 to d 1 within a genotype. One symbol indicates a $P < 0.05$.

Discussion

In the present work, we produced a model of genetic transcortin variability with animals displaying 100, 50, or 0% of liver Cbg mRNA and plasma CBG protein. Our exploration of the HPA axis regulation under basal conditions showed data similar to those obtained in the few human patients described with heterozygous or homozygous null mutation in the *Serpina6* gene encoding transcortin. Indeed, both in mice and human, absence of CBG leads to markedly decreased total glucocorticoid levels across the circadian cycle, elevated free

fraction of glucocorticoids (~20–30%), elevated albumin bound fraction (~40%), and no apparent change in free glucocorticoid peak concentrations (*i.e.* morning in human and evening in mice) (20, 21). For mutant mice with only one Cbg-deficient allele like in human patients with 50% CBG levels, the free fraction of corticosterone is slightly increased (12.3 *vs.* 9.4% in Cbg+/+), but total glucocorticoid levels are comparable to controls in resting conditions. This absence of effect may be explained by the fact that CBG levels are in excess in resting conditions [68% of CBG is reported to circulate unbound in many species (8)]; thus, a 50% deficiency in CBG is still enough for normal basal glucocorticoid binding. As in human CBG-deficient patients, basal HPA axis regulation was not impaired in any mice groups. Indeed, free corticosterone levels at the beginning of the active phase were similar across genotypes. Second, no significant differences were found in the expression of glucocorticoid target genes or in genes involved in the regulation of the HPA axis in resting conditions. Third, the pattern of secretion of corticosterone over the circadian cycle was similar between genotypes. Thus, these data confirm that the basal corticosterone tone and the regulation of the HPA axis are driven by free and not total corticosterone. Contrary to interpretations by others, we therefore believe that Cbg^{-/-} mice are a good model for the human condition of CBG deficiency (22). In their study of another mouse model of transcortin deficiency, Petersen *et al.* (23) defend the idea that their CBG knockout mice are unable to “sense” appropriately free corticosterone levels, based on their observation of elevated free corticosterone concentrations in Cbg^{-/-} mice together with elevated ACTH levels. However, we have several concerns from the measures done in this study: blood was collected only in the morning, *i.e.* at the nadir of the circadian peak of corticosterone; the total corticosterone and ACTH values presented correspond to stress levels, and the free fractions of corticosterone are very low (~0.7% for Cbg+/+ and ~15% for Cbg^{-/-}). In our hands, ACTH levels are on the high end compared with previous work that found concentrations around 100 pg/ml at rest in the morning, but we found no statistical difference between genotypes. Furthermore, we did not find differences between genotypes in CRH mRNA expression in hypothalamus.

After stress, the CBG-deficient mice showed a pattern of corticosterone secretion similar to the wild-type controls, *i.e.* a marked increase of total corticosterone levels followed by a progressive return to basal levels. However, the elevation of total corticosterone levels in CBG-deficient mice is moderate for Cbg^{+/-} and weak for Cbg^{-/-} compared with Cbg+/+. In these stress conditions, CBG levels are saturated with corticosterone binding and in a

quicker way in Cbg^{+/-} than Cbg+/+, explaining the difference in total corticosterone values. Furthermore, again in contrast to rest levels, the greater free fraction of corticosterone in transcortin-deficient mice does not compensate the smaller corticosterone rise after the 20-min stress. Consequently, free corticosterone levels are subnormal in the mutant mice. These results indicate the important role of CBG in determining glucocorticoid pool size (*i.e.* the mass of cortisol/corticosterone circulating) and are in agreement with previous data obtained in human subjects where CBG was shown to influence cortisol half-life, pool size, and volume distribution (24). Precise evaluation of corticosterone clearance is difficult to assess in small animals such as mice because it is very rapid. In their study, Petersen *et al.* (23) found that 5 min after injection of tritiated corticosterone, there was 10% left of the radioactive steroid in the plasma of Cbg+/+ *vs.* 2.5% in Cbg^{-/-}, suggesting a 4-fold higher clearance in mutant mice. This higher clearance may explain our finding of similar kinetics of plasma corticosterone after stress despite subnormal free corticosterone concentrations in transcortin-deficient mice.

These results of altered rise in free corticosterone after stress in our Cbg-deficient mice prompted us to evaluate its possible impact on behavior in Cbg-deficient mice. Our behavioral data show that in situations of low or moderate stress Cbg^{-/-}, Cbg^{+/-}, and Cbg+/+ mice are indistinguishable with respect to exploration and anxiety-related traits. Petersen *et al.* (23) found diminished activity scores in Cbg^{-/-} mice that they attribute to fatigue syndrome. It may be that they did their measures in the habituation phase and/or in more stressful conditions. Our results on 72 h of activity recording do not support the hypothesis of increased fatigue in our mutant mice, and anyway, we believe that fatigue syndrome cannot be recapitulated simply by a measure of locomotor activity. Similar observations of equivalent exploration and anxiety were made in mice with altered levels of GRs. Indeed, GR^{+/-} mice showing 50% reduction in GR expression and YGR mice that have twice the amount of GR compared with wild-type animals, all display equivalent behavior in basal- or mild-stress situations (25). In addition, no differences in general activity or time spent in the center of the open field were observed in mice models with brain-specific GR or MR genetic manipulation (knockout or overexpression) (26–29). Collectively, these data suggest that variation in glucocorticoid signaling has no or little impact on exploratory and anxiety-related behaviors after a mild stress.

However, in paradigms of intense and uncontrollable stress, transcortin-deficient mice displayed clear altered behavior compared with wild-type mice. First, transcortin-deficient mice showed markedly increased learned

helplessness with a higher number of escape failures and decreased number of avoided footshocks. Furthermore, we demonstrated that these behavioral responses are associated with decreased levels of free corticosterone in Cbg-deficient mice in plasma and decreased expression of Egr-1 gene in hippocampus. Recently, Egr-1 was shown to mediate stress-related behavioral effects of glucocorticoids in hippocampus (30). Its decreased expression is in accordance with reduced glucocorticoid signaling in the brain of our mutant mice, because the rapid (within 30 min) modification in Egr-1 expression is strictly regulated by glucocorticoid levels in brain independently from MAPK pathway signaling (30). There was no difference in the expression of the other genes tested. Because we killed the animals just after the test, it is not surprising that only immediate early genes such as Egr-1 were found affected. Basal levels of total corticosterone were altered in each group on d 2, showing that the mice had not recovered a normal HPA tone after 24 h. Whether CBG levels were suppressed in Cbg+/+ and Cbg+/- 24 h after the footshocks as reported in rat (31) could not be assessed because the blood volume collected at the tail of the animals was not sufficient.

Overall, our data are in good agreement with the literature, because low glucocorticoid levels have been associated with increased learned helplessness in rats. Indeed, both adrenalectomy and treatment with the glucocorticoid antagonist RU38486 enhance the development of learned helplessness in Sprague Dawley rats, an effect that is reversed by corticosterone (32). Additionally, the congenital learned helpless rat, genetically selected for susceptibility to learned helplessness behavior, has basal corticosterone levels similar to control animals, but exhibits corticosterone hyporesponsiveness to major stressors, similarly to our Cbg+/- mice (33). Finally, the GR+/- mice show increased learned helplessness, no differences in basal and slightly higher corticosterone levels after stress (25). The latter finding is not contradictory with our data because elevated corticosterone levels will not be effective in the brain of GR+/- mice. This higher despair-like behavior found in Cbg-deficient mice was confirmed in the forced-swimming test where Cbg-/- in particular showed a higher immobility time compared with Cbg+/+, especially if 1-h restraint is performed before the forced-swimming test. Second, our results on cocaine sensitization are in accordance with decreased brain glucocorticoid signaling in transcortin-deficient mice. Indeed, we found that sensitization of the locomotor response to cocaine is clearly suppressed in Cbg-/- mice and only a moderate sensitization is seen in Cbg+/- mice. Glucocorticoid facilitation of drug sensitization is a phenomenon described 20 yr ago in rats. Adrenalectomy

resulting in depletion of glucocorticoids was shown to suppress amphetamine sensitization in rat but can be restored by dexamethasone replacement (34). More recently, cocaine sensitization was found suppressed in mice deleted for brain GR (35) and increased in mice overexpressing the GR in the central nervous system (28).

Therefore, our endocrine as well as behavioral results all converge to the finding of decreased glucocorticoid levels and signaling in Cbg-deficient mice after strong stress. Overall, our data are not contradictory with the findings reported in the study of Petersen *et al.* (23). The main difference between the two studies is the free glucocorticoid response after stress that we found reduced, whereas Petersen *et al.* (23) found it increased or equivalent compared with wild-types animals. Therefore, we conclude that Cbg deficiency leads to an insufficient glucocorticoid response to stress but normal resting levels, whereas Petersen *et al.* (23) believe that transcortin deficiency results in increased ACTH activity and hyporesponsiveness to glucocorticoids even in resting conditions. We cannot rule out that the apparent discrepancy in free corticosterone levels stem from the models themselves, for example the influence of the genetic background, but we favor the idea of methodological differences. To our benefit, our results fit better to the human condition of transcortin deficiency than Petersen *et al.* (23) data.

Both hypercortisolemia and hypocortisolemia have been reported to be associated with depressive states in human subjects (36–38). The hypocortisolism usually resulting from exhaustion of the HPA axis as a result of chronic stress is often associated with depression in fibromyalgia, burnout, and chronic fatigue syndromes (1, 39). Down-regulation of the HPA axis is also reported in atypical depression linked with fatigue and hyperphagia leading to increased body mass index (38). The increased learned helplessness associated with low corticosterone levels observed in our deficient mice is congruent with these depression subtypes. The role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders has been reviewed recently (40). According to the authors, both hypocortisolism and decreased glucocorticoids responsiveness are found associated with stress-related pathologies. As predicted by these authors, alteration in binding protein such as transcortin may lead to hypocortisolism and to decreased glucocorticoids signaling that will then influence the development of stress-related disorders. Thus, the data obtained on our transcortin-deficient mice fit with this hypothesis. Interestingly, most of the patients genetically deficient in CBG display a depressed mood, fatigue, and have a high body mass index (20, 21, 22). Such severe CBG mutations are rare, but variations in plasma transcortin levels are very frequent in

human (41) and animal populations (11, 42). This variability may be genetic or secondary to intake of estrogen-containing contraceptives stimulating CBG production, or due to variations in insulin or IL-6 levels that inhibit transcortin (43–45).

In conclusion, we show that partial or total deficiency of plasma transcortin in mice does not affect the HPA axis functioning in resting conditions but leads to glucocorticoid hyposignaling after an intense stress and increased depression-like behaviors. The putative role of corticosterone-CBG complexes on membrane receptors proposed by some authors (46, 47) has not been studied and therefore cannot be excluded. Thus, transcortin plays a subtle but critical role in endocrine and behavioral stress responses that may explain the vulnerability to fatigue and depressive symptoms in transcortin-deficient patients. For more information, see the supplemental data published on The Endocrine Society's Journals Online web site at <http://endo.endojournals.org>.

Acknowledgments

We thank Dr. H. Vaudry (University of Rouen, France) for providing the anticorticosterone antibody, Prof. G. L. Hammond (University of British Columbia, Vancouver, Canada) for the gift of mouse CBG antiserum, A. Fayoux for her technical help, and A. Foury, J. B. Corcuff, P. Barat, and Geoff Hammond for helpful discussions. Real-time PCR experiments presented in the present publication were performed at the Genotyping and Sequencing facility of Bordeaux.

Address all correspondence and requests for reprints to: Marie-Pierre Moisan, Institut National de la Recherche Agronomique (INRA), Unité Mixte de Recherche 1286 PsyNuGen, Centre National de la Recherche Scientifique 5226, Université de Bordeaux 2, F-33076 Bordeaux, France. E-mail: mpmoisan@bordeaux.inra.fr.

A.M.M. is the recipient of a PhD grant cofunded by the Conseil Régional d'Aquitaine (20081301032) and INRA Animal Genetics department. The genotyping and sequencing facility is supported by Conseil Régional d'Aquitaine Grants 20030304002FA and 20040305003FA and by the European Union Grant FEDER 2003227.

Disclosure Summary: E.R., J.-C.H., C.T., A.D., A.M.M., M.C., L.P., J.-P.K. have nothing to declare. P.M. and M.-P.M. are inventors of French patent no. FR2831890 (A1).

References

1. McEwen BS 1998 Stress, adaptation, and disease. Allostasis and allostatic load. *Ann NY Acad Sci* 840:33–44
2. Chrousos GP 1998 Stress as a medical and scientific idea and its implications. *Adv Pharmacol* 42:552–556
3. de Kloet ER 2003 Hormones, brain and stress. *Endocr Regul* 37: 51–68

4. Piazza PV, Le Moal M 1998 The role of stress in drug self-administration. *Trends Pharmacol Sci* 19:67–74
5. Mormède P, Courvoisier H, Ramos A, Marissal-Arvy N, Ousova O, Désautés C, Duclos M, Chaouloff F, Moisan MP 2002 Molecular genetic approaches to investigate individual variations in behavioral and neuroendocrine stress responses. *Psychoneuroendocrinology* 27:563–583
6. Colvis CM, Pollock JD, Goodman RH, Impey S, Dunn J, Mandel G, Champagne FA, Mayford M, Korzus E, Kumar A, Renthall W, Theobald DE, Nestler EJ 2005 Epigenetic mechanisms and gene networks in the nervous system. *J Neurosci* 25:10379–10389
7. Dallman MF, Pecoraro NC, La Fleur SE, Warne JP, Ginsberg AB, Akana SF, Laugero KC, Houshyar H, Strack AM, Bhatnagar S, Bell ME 2006 Glucocorticoids, chronic stress, and obesity. *Prog Brain Res* 153:75–105
8. Gayrard V, Alvinerie M, Toutain PL 1996 Interspecies variations of corticosteroid-binding globulin parameters. *Domest Anim Endocrinol* 13:35–45
9. Désautés C, Bidanel JP, Milan D, Iannuccelli N, Amigues Y, Bourgeois F, Caritez JC, Renard C, Chevalet C, Mormède P 2002 Genetic linkage mapping of quantitative trait loci for behavioral and neuroendocrine stress response traits in pigs. *J Anim Sci* 80:2276–2285
10. Ousova O, Guyonnet-Duperat V, Iannuccelli N, Bidanel JP, Milan D, Genêt C, Llamas B, Yerle M, Gellin J, Chardon P, Emptoz-Bonneton A, Pugeat M, Mormède P, Moisan MP 2004 Corticosteroid binding globulin: a new target for cortisol-driven obesity. *Mol Endocrinol* 18:1687–1696
11. Guyonnet-Dupérat V, Gevorkian N, Plastow GS, Evans G, Ousova O, Croisette C, Foury A, Richard E, Mormède P, Moisan MP 2006 Functional implication of an Arg307Gly substitution in corticosteroid-binding globulin, a candidate gene for a quantitative trait locus associated with cortisol variability and obesity in pig. *Genetics* 173: 2143–2149
12. Solberg LC, Baum AE, Ahmadiyeh N, Shimomura K, Li R, Turek FW, Takahashi JS, Churchill GA, Redei EE 2006 Genetic analysis of the stress-responsive adrenocortical axis. *Physiol Genomics* 27:362–369
13. Dupé V, Davenne M, Brocard J, Dollé P, Mark M, Dierich A, Chambon P, Rijli FM 1997 In vivo functional analysis of the Hoxa-1 3' retinoic acid response element (3'RARE). *Development* 124:399–410
14. D'Elia M, Patenaude J, Hamelin C, Garrel DR, Bernier J 2005 Corticosterone binding globulin regulation and thymus changes after thermal injury in mice. *Am J Physiol Endocrinol Metab* 288:E852–E860
15. Hammond GL, Lähteenmäki PL, Lähteenmäki P, Luukkainen T 1982 Distribution and percentages of non-protein bound contraceptive steroids in human serum. *J Steroid Biochem* 17:375–380
16. Hammond GL, Lähteenmäki PL 1983 A versatile method for the determination of serum cortisol binding globulin and sex hormone binding globulin binding capacities. *Clin Chim Acta* 132:101–110
17. Cole TJ, Harris HJ, Hoong I, Solomon N, Smith R, Krozowski Z, Fullerton MJ 1999 The glucocorticoid receptor is essential for maintaining basal and dexamethasone-induced repression of the murine corticosteroid-binding globulin gene. *Mol Cell Endocrinol* 154:29–36
18. Henn FA, Vollmayr B 2005 Stress models of depression: forming genetically vulnerable strains. *Neurosci Biobehav Rev* 29:799–804
19. Lu A, Steiner MA, Whittle N, Vogl AM, Walser SM, Ableitner M, Refojo D, Ekker M, Rubenstein JL, Stalla GK, Singewald N, Holsboer F, Wotjak CT, Wurst W, Deussing JM 2008 Conditional CRH overexpressing mice: an animal model for stress-elicited pathologies and treatments that target the central CRH system. *Mol Psychiatry* 13:989
20. Emptoz-Bonneton A, Cousin P, Seguchi K, Avvakumov GV, Bully C, Hammond GL, Pugeat M 2000 Novel human corticosteroid-binding globulin variant with low cortisol-binding affinity. *J Clin Endocrinol Metab* 85:361–367
21. Torpy DJ, Bachmann AW, Grice JE, Fitzgerald SP, Phillips PJ, Whitworth JA, Jackson RV 2001 Familial corticosteroid-binding globulin deficiency due to a novel null mutation: association with fatigue and relative hypotension. *J Clin Endocrinol Metab* 86:3692–3700

22. Torpy DJ, Ho JT 2007 Corticosteroid-binding globulin gene polymorphisms: clinical implications and links to idiopathic chronic fatigue disorders. *Clin Endocrinol* 67:161–167
23. Petersen HH, Andreassen TK, Breiderhoff T, Bräsen JH, Schulz H, Gross V, Gröne HJ, Nykjaer A, Willnow TE 2006 Hyporesponsiveness to glucocorticoids in mice genetically deficient for the corticosteroid binding globulin. *Mol Cell Biol* 26:7236–7245
24. Bright GM 1995 Corticosteroid-binding globulin influences kinetic parameters of plasma cortisol transport and clearance. *J Clin Endocrinol Metab* 80:770–775
25. Ridder S, Chourbaji S, Hellweg R, Urani A, Zacher C, Schmid W, Zink M, Hörtnagl H, Flor H, Henn FA, Schütz G, Gass P 2005 Mice with genetically altered glucocorticoid receptor expression show altered sensitivity for stress-induced depressive reactions. *J Neurosci* 25:6243–6250
26. Boyle MP, Kolber BJ, Vogt SK, Wozniak DF, Muglia LJ 2006 Forebrain glucocorticoid receptors modulate anxiety-associated locomotor activation and adrenal responsiveness. *J Neurosci* 26:1971–1978
27. Berger S, Wolfer DP, Selbach O, Alter H, Erdmann G, Reichardt HM, Chepkova AN, Welzl H, Haas HL, Lipp HP, Schütz G 2006 Loss of the limbic mineralocorticoid receptor impairs behavioral plasticity. *Proc Natl Acad Sci USA* 103:195–200
28. Wei Q, Lu XY, Liu L, Schafer G, Shieh KR, Burke S, Robinson TE, Watson SJ, Seasholtz AF, Akil H 2004 Glucocorticoid receptor overexpression in forebrain: a mouse model of increased emotional lability. *Proc Natl Acad Sci USA* 101:11851–11856
29. Rozeboom AM, Akil H, Seasholtz AF 2007 Mineralocorticoid receptor overexpression in forebrain decreases anxiety-like behavior and alters the stress response in mice. *Proc Natl Acad Sci USA* 104:4688–4693
30. Revest JM, Di Blasi F, Kitchener P, Rougé-Pont F, Desmedt A, Turiault M, Tronche F, Piazza PV 2005 The MAPK pathway and Egr-1 mediate stress-related behavioral effects of glucocorticoids. *Nat Neurosci* 8:664–672
31. Fleshner M, Deak T, Spencer RL, Laudenslager ML, Watkins LR, Maier SF 1995 A long-term increase in basal levels of corticosterone and a decrease in corticosteroid-binding globulin after acute stressor exposure. *Endocrinology* 136:5336–5342
32. Greenberg L, Edwards E, Henn FA 1989 Dexamethasone suppression test in helpless rats. *Biol Psychiatry* 26:530–532
33. King JA, Abend S, Edwards E 2001 Genetic predisposition and the development of posttraumatic stress disorder in an animal model. *Biol Psychiatry* 50:231–237
34. Rivet JM, Stinus L, LeMoal M, Mormède P 1989 Behavioral sensitization to amphetamine is dependent on corticosteroid receptor activation. *Brain Res* 498:149–153
35. Deroche-Gamonet V, Sillaber I, Aouizerate B, Izawa R, Jaber M, Ghzoul S, Kellendonk C, Le Moal M, Spanagel R, Schütz G, Tronche F, Piazza PV 2003 The glucocorticoid receptor as a potential target to reduce cocaine abuse. *J Neurosci* 23:4785–4790
36. Heim C, Ehlert U, Hellhammer DH 2000 The potential role of hypocortisolism in the pathophysiology of stress-related bodily disorders. *Psychoneuroendocrinology* 25:1–35
37. Bremner MA, Deeg DJ, Beekman AT, Penninx BW, Lips P, Hoogendijk WJ 2007 Major depression in late life is associated with both hypo- and hypercortisolemia. *Biol Psychiatry* 62:479–486
38. Gold PW, Chrousos GP 2002 Organization of the stress system and its dysregulation in melancholic and atypical depression: high vs low CRH/NE states. *Mol Psychiatry* 7:254–275
39. McEwen BS 2007 Physiology and neurobiology of stress and adaptation: central role of the brain. *Physiol Rev* 87:873–904
40. Raison CL, Miller AH 2003 When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. *Am J Psychiatry* 160:1554–1565
41. Fernandez-Real JM, Pugeat M, Grasa M, Broch M, Vendrell J, Brun J, Ricart W 2002 Serum corticosteroid-binding globulin concentration and insulin resistance syndrome: a population study. *J Clin Endocrinol Metab* 87:4686–4690
42. Geverink NA, Foury A, Plastow GS, Gil M, Gispert M, Hortós M, Furnols M, Gort G, Moisan MP, Mormède P 2006 Cortisol-binding globulin and meat quality in five European lines of pigs. *J Anim Sci* 84:204–211
43. Crave JC, Lejeune H, Brébant C, Baret C, Pugeat M 1995 Differential effects of insulin and insulin-like growth factor I on the production of plasma steroid-binding globulins by human hepatoblastoma-derived (Hep G2) cells. *J Clin Endocrinol Metab* 80:1283–1289
44. Emptoz-Bonneton A, Crave JC, Lejeune H, Brébant C, Pugeat M 1997 Corticosteroid-binding globulin synthesis regulation by cytokines and glucocorticoids in human hepatoblastoma-derived (HepG2) cells. *J Clin Endocrinol Metab* 82:3758–3762
45. Tsigos C, Kyrou I, Chrousos GP, Papanicolaou DA 1998 Prolonged suppression of corticosteroid-binding globulin by recombinant human interleukin-6 in man. *J Clin Endocrinol Metab* 83:3379
46. Maitra US, Khan MS, Rosner W 1993 Corticosteroid-binding globulin receptor of the rat hepatic membrane: solubilization, partial characterization, and the effect of steroids on binding. *Endocrinology* 133:1817–1822
47. Pusch L, Wegmann S, Caldwell JD, Jirikowski GF 2009 Expression of corticosteroid-binding globulin in human astrocytoma cell line. *Cell Mol Neurobiol* 29:583–588